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                                                             Abstract 
Background:   Concerns about opioid prescribing in the United States have been rising (Centers 
for Disease Control and Prevention [CDC], 2016). Assessing pain scores, along with urine 
toxicology screenings can provide information to both patients and providers about prescription 
opioids. 
Objectives:  The purpose of this retrospective chart review study was to compare numeric pain 
scores and urine toxicology results between two different groups of patients who were being 
prescribed daily <90mg opioid dosing versus ≥ 90mg opioid dosing.  
Methods:   This retrospective chart review sample was of 134 adult chronic pain patients at one 
pain management clinic. Patients’ average numeric pain rating while using opioids for a year in 
the <90mg daily opioid dosing versus ≥ 90mg daily opioid dosing group at initial visit and after a 
year on opioids were analyzed. Urine toxicology screening results were analyzed.  
Results:  Of the 134 patients, 9 (6.7%) failed urine toxicology screenings, 6 from the (<90mg 
MED low dose group) and 3 from the (≥90mg MED high dose group). Of 134 patients, n=77 
(57.5%) improved their pain score in the year, n=57 (42.5%) had no improvement or worse pain 
on opioids. Insurance type: of the 134 patients, Medicaid 32.1% (n=43), Medicare 29.1% (n=39) 
Workers Compensation 19.4% (n=26), and private insurance 18.7% (n=25).  
Conclusions:  This study indicates insurance type was a statistically significant variable and 
indicates further research is needed within the two dosing groups to understand how this may 
influence changes to opioid prescribing. Urine toxicology failures between both dosing groups 
was only 6.7%. 
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                                                              Background 
     In 2016 the Centers for Disease Control and Prevention (CDC) issued guidelines for 
prescribers who are managing chronic pain patients. These guidelines generally try to lower daily 
dosing to under 50mg MED and at most daily dosing of 90 mg MED, plus to use significant 
medical justification if prescribing over 90MED (CDC, 2016). These new guidelines have given 
insurance companies justification to refuse payment for higher dosing despite many being on 
these higher daily doses.  In the 1990’s and early 2000’s in America, chronic non-cancer pain 
patients  had been managed with opioid therapy, as well as adjunctive approaches, with the full 
support of multiple medical and national research institutions (Edlund, Martin, Russo, Devries, 
Braden & Sullivan, 2014). Healthcare providers today are currently seeing an increase in 
recommendations from multiple professional organizations that indicate changes to how opioids 
for chronic pain could be prescribed and managed more safely. Prior to these new 
recommendations, providers were encouraged to educate patients that under-treatment of acute 
pain leads to chronic pain, and opioids were given to avoid this complication. The concerns 
about misuse of opioids were generally limited in the literature until this decade. Some studies 
now indicate higher misuse rates for patients who use larger daily doses of opioids (Bohnert et 
al., 2011). Taking prescription opioids for longer periods of time or in higher dosages can 
increase the risk of opioid misuse disorder, overdose, and death (CDC, 2018).  From 1999 to 
2017, greater than 217,000 people died in the United States from overdoses related to 
prescription opioids (CDC, 2018).  More than ever, patient safety with the use of opioids is now 
in question. Providers are now however left with questions about their prescribing practices and 
patient outcomes with the varying doses of chronically used opioids for chronic pain. Some 
providers at pain clinics take care of patients who are on much higher dosing of opioids than the 
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current general recommendations. They are concerned about the current status of their patients 
who may have been on opioids for chronic pain for longer than a decade and have done well 
physically, mentally, with no signs of misuse.  
     This retrospective Institutional Review Board (IRB) exempt study explored a single practice’s 
prescribing of opioids by dosing of high and low groups, and their patients’ average numeric 
pain score initially, after a year on opioids and their urine toxicology screening results.                                                       
                                                    Problem Statement 
     The CDC (2016) have issued their recommendations to address opioid dosing for chronic pain 
management, generating specific daily dosing levels of opioids for chronic noncancerous pain 
patients. These recommendations are meant to give guidance to providers when prescribing 
opioids for chronic non-cancer pain patients. It is important to realize the CDC’s guidelines do 
not prohibit the use of opioids over 90 mg daily MED. They ask that the higher dosing (>90mg 
daily MED) be done with caution and that the provider justify the decision. The guidelines are 
further aimed toward primary care of chronic pain patient. However, these guidelines are being 
applied without distinction in the chronic pain management clinic setting by insurance 
companies.  The CDC opioid dosing recommendations focused on management of chronic pain 
with the exception of cancer care, hospice and palliative care. These exceptions are because 
comfort care is often the goal when end of life is imminent.  
     Significant controversy and concern from multiple medical organizations surround the CDC’s 
strict recommendation and limits of daily opioid dosages. The American Medical Association 
(AMA) (2016) states that the current CDC’s opioid prescribing guidelines are not based on 
risk/benefit studies for patients but on risk studies alone. Further, another organization argued 
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that these guidelines should not be used to limit therapy for any one patient (American Pain 
Society, 2016). Additionally, the American Academy of Pain Management (2016) is concerned 
with the recommended dosing limit that suggests no more than 90mg of morphine equalization 
dosing (MED) be given daily, despite the reality that much higher doses have been helpful to 
patients. These higher doses have been perceived as safe in previous years (American Pain 
Society, 2009). The American Academy of Pain Medicine (2016) reports that they have 
significant concerns regarding the methodology of the evidence which was cited by the current 
CDC recommendations. The American Academy of Pain Medicine (2016) feels more research 
needs to be done before limiting daily dosing levels of opioids for all noncancerous chronic pain 
patients. Therefore, multiple groups such as the AMA, American Pain Society, American 
Academy of Pain Management, and the American Academy of Pain Medicine all state concerns 
about the CDC’s research and new guidelines. 
     These conflicting views over the daily dosing of opioids leave providers, patients and 
communities trying to determine what is best for their clinical setting. Providers want to help 
patients who have unique pain levels and misuse histories by individualizing daily dosing levels 
of opioids that help reduce pain, minimize misuse, and improve function. One of the questions 
that I examined in my study was, would there be a difference in the initial visit numeric pain 
levels versus follow up numeric pain levels and urine toxicology results at different dosing 
levels, which are: high ≥90 daily Morphine Equalization Dose (MED) versus low <90 daily 
MED dosing of daily opioids for chronic pain patients at a single practice? 
     The suggested relationship between the higher daily dose of opioids and higher misuse rates 
is a concern for communities, however, providers have found that some patients currently on 
higher dosages are not necessarily susceptible to misuse (Sullivan & Howe, 2013).  These 
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patients often have low pain levels and function for decades even with these higher doses of 
medication. Inappropriately lowering dosing of opioids has led to negative mental and physical 
repercussions on patients functioning (Anson, 2016).  
      According to the American Pain Society (2009), anywhere from 1%-8% of people will 
develop an opioid misuse disorder when using any opioid. Chou (2015) in a systematic review 
states that in the pain clinic setting, prevalence of opioid misuse ranges from 8% to 16%. . 
“Misuse is generally defined as an intentional therapeutic use of a drug in an inappropriate way” 
(Cheatle, 2015).  Recent retrospective studies often measure only the opioid misuse rates and 
infrequently the pain reduction scores and benefits to the patients (Boscarino et al., 2016). The 
results of this current retrospective chart review study provides valuable feedback for dosing 
levels, initial average pain scores, average pain scores after a year on opioids and urine 
toxicology results, to patients and providers at a single pain management practice. 
                                                                   Purpose      
     The purpose of this retrospective chart review study was to compare patients’ initial average 
pain scores, average pain scores after a year on opioids and urine toxicology results between two 
groups of patients who were prescribed within the general current Centers for Disease Control 
and Prevention dosing guidelines (<90 MED), and the other group was above the dosing 
recommendations (≥90MED). Inclusion criteria for participants was that patients had been on 
opioids for at least year in this study, had a chronic pain diagnosis of the top four seen at the 
clinic which were; spinal stenosis, spinal degenerative disc disease, spinal facet arthropathy, 
multiple areas of arthritis, an initial visit numeric pain score, a current urine opioid urine 
toxicology, follow up numeric pain rating score, and be greater than 18 years old.  
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                                                               Specific Aims 
     The specific aims of the study were to measure patient outcomes from the pain management 
outpatient clinic for the following variables: 
1. Compare the results of opioid urine toxicology screenings in patients receiving daily 
dosing of <90 mg morphine equalization dosing (MED) versus the ≥90mg MED. 
2. Compare the numeric average pain score since last visit of patients to the initial numeric 
average pain score for those receiving daily dosing of <90mg MED versus ≥ 90 mg 
MED.  
3. Compare the daily <90mg daily MED versus ≥ 90 mg daily MED opioid dosing levels by 
gender differences. 
4. Compare the daily <90mg daily MED versus ≥ 90mg daily MED opioid dosing levels by 
insurance type. 
5. Describe and compare the demographics of patients by age, chronic pain diagnosis, and 
improvement and/or decline of pain scores on opioids. 
                                              Significance 
     Improving population health and health system performance are two of the Institute of 
Healthcare Improvement’s Triple Aim Initiatives (Institute of Healthcare Improvement, 2012). 
Opioid guidelines that improve health system performance and population health in any 
community are important to the country. The data generated from this study may offer insight to 
guide advanced nurse practitioners and other providers managing chronic pain patients’ 
prescriptions.  
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     The National Institutes of Health (NIH) gathered researchers in spring 2018 at the NIH at a 
symposium, to discuss chronic pain management and the opioid crisis (National Institute of 
Health [NIH], 2018). The culture of opioid prescribing is changing and pain practice providers 
want to be current yet, also sensitive to chronic pain patients’ needs and those of their 
communities.                                                      
                                                      Literature Review   
     The opioid crisis has demanded political, academic, financial and community attention in the 
last decade. Concerns within healthcare about the misuse of opioids have increased. According 
to Dahlhmaer et al., 2016, approximately 20.4% percent of the adults in the United States have 
chronic pain.  An estimated 5.1 million people used prescription pain relievers for non-medical 
reasons in the quality improvement study by Hamill-Ruth, Larriviere & McMasters (2013). 
Cheatle (2015) defines misuse of opioids generally as an intentional therapeutic use of a drug in 
an inappropriate way. For example, a patient may take pain relievers in excess of prescription, 
which would constitute misuse. The following sections provide literature on some of the key 
variables that were examined in this study. 
Opioid Dosing   
     To help understand opioid dosage rates, a retrospective study by (Morasco et al., 2017) 
divided prescription dosing by levels to assess outcomes of opioids. This study used low daily 
dosage of (5-20 mg MED), moderate daily dose (20.1-50mg MED) and higher daily dosing 
(50.1-120mg MED) for patients with musculoskeletal pain diagnoses and on long term opioid 
therapy. In this study (Morasco et al., 2017) rates of misuse were 7.6-8.2% for all daily dosage 
groups, with a slightly lower prevalence of opioid misuse of 7.8% for the high daily dosing level 
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group. In addition, (Morasco et al., 2017) states the higher dosing of opioids with lower misuse 
rates, may mean the patients are using other substances to supplement their pain relief but not 
reporting this. Studies vary in the daily opioid dosing levels due to lack of agreement on what are 
high and low levels of opioid daily dosing. For example, a study by Gomes (2011) which was a 
population based case controlled study, stated that 200mg daily MED or more was considered a 
high dose. In a retrospective study by (Chung et al., 2016) the study used 60mg of daily opioid 
dosing as the high dosing level.  
Opioid Urine Toxicology Screening   
     Hamill-Ruth, Larriviere & McMasters (2013) state that opioid urine drug screening is useful 
in identifying substances currently in the patient’s system. Opioid urine toxicology information 
is an important point of care service and tests for classes of medication such as opioids. The 
work by Keary, Wang, Moran, Zayas & Stern (2012) add that urine toxicology testing using gas 
chromatography (GC) followed by mass spectroscopy (MS) is considered the gold standard for 
confirmatory urine toxicology testing. One study rates urine toxicology results with an 89% 
reliability and validity score (Manchikanti, Malla, Wargo & Fellows, 2011).  A retrospective 
study by Gupta (2011) helps define normal (positive) urine screenings versus abnormal 
(negative) urine screenings. A normal (positive) urine screening is defined as a one that has 
expected findings based upon prescribing, the prescription monitoring program monthly script 
data, and patients stated use. An abnormal (negative) urine is defined as 1) the absence of a 
prescribed opioid, 2) the presence of an additional non-prescribed controlled substance, 3) 
detection of an illicit substance, or 4) an adulterated urine sample (Gupta, 2011).  
Chronic Pain Level Score   
OPIOID DAILY DOSING  10 
     The outcomes for the patient in terms of decreasing pain levels or not with daily opioids for 
chronic non-cancer pain has fewer studies than the misuse rates of opioid studies in literature. 
The retrospective study by (Chung et al., 2016) used dosing of opioids less than 60mg daily 
MED to assess pain levels. This study found patients’ pain levels were lower on longer term 
daily opioids of at least two months.  An office based retrospective study of 140 patients by 
(Zhou et al., 2017) looked at tapering opioids until abstinence versus those who stayed on 
opioids (average dosing 83.5-123.4mg daily MED). The study showed statistical significance for 
decreased numeric pain levels for both groups despite the differing dosing levels of opioids. A 
retrospective study of 246 patients by (Henry, Wilsey, Melnikow and Losif, 2015) found only 
one point difference on the pain level numeric scale of patients in any of the different daily 
dosing levels starting at 30mg daily MED or more of opioids. A large population (1,781) study 
comparing scheduled dosing (325 people) versus pain contingent dosing of opioids (967 people) 
revealed large differences in opioid dosage for pain management. This study used daily opioid 
dosing at 37mg daily MED for the pain contingent group versus 97 mg daily MED for the time 
scheduled group, yet the pain levels between the two groups were similar (Von Korff et al., 
2011). None of the previous studies used the current CDC general recommendations as 
guidelines for their studies because the CDC guidelines were not published yet. Providers are left 
to discover if there is a pain level improvement or not within the current CDC guidelines (2016) 
for their patients within <90 mg daily MED versus ≥ 90 mg daily MED.  
    The literature also reveals that the numeric pain rating scale provides sufficient discriminative 
power for chronic pain patients to describe their pain intensity (Hjermstad, 2011). Further, the 
reliability is r=0.96 and validity of the numeric pain scale is v=0.86 (Ferraz et al., 1990). 
Gender Differences   
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     A recent cross sectional, self-reported study by (Han et al., 2015) suggests that gender 
differences are seen in prescription opioid misuse. This study reported a male prevalence of 2.9% 
and a female prevalence of 1.4% for an opioid misuse disorder, but it was not reported as 
statistically significant. Another population study, with 2,039 patients using electronic health 
records, reports that women more than men (54% vs 46%) have opioid misuse disorders 
(Boscarino et al., 2016). Darnell, Stacey and Chou, (2012) meta-analysis study adds that women 
report more chronic pain than men, and may be treated at higher opioid dosages. Results are 
mixed and not conclusive. 
Insurance Type   
     The survey study by (Han et al., 2015) reported that private insurance rate of opioid misuse is 
1.6% and Medicaid is 3.5%. In a systematic database search, Voon, Karamouzian & Kerr (2017) 
reported there were no demographic factors such as insurance type that were consistently 
different between those with prescription opioid use disorder and those without. For adults older 
than 65 the prevalence of opioid use disorder for those on Medicaid and other public coverage is 
higher than those with private insurance (Jeffery et al., 2018). The study by (Jeffery et al., 2018) 
a retrospective cohort study from 2007-16 with 48 million individuals, showed opioid use in 
commercial beneficiaries at 14%, Medicare beneficiaries by age ≥ 65 at 26% and disabled 
Medicare beneficiaries at 52%.  
Chronic Pain Diagnoses   
     “Chronic pain is defined as any pain lasting longer than 12 weeks” (NIH, 2011, p.2). Pain is 
very personal and is by nature a subjective experience. The top four chronic pain diagnoses in 
this study were used to give readers an idea of the population of study to compare with their own 
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population. These diagnoses are spinal stenosis of the cervical, lumbar, or thoracic regions, 
multiple areas of arthritis, degenerative disc disease of the lumbar, cervical, or thoracic regions, 
and facet arthropathy of any region of the spine. 
     There are no tests to measure and locate pain with precision, but the numeric pain rating scale 
is used as a starting point of measurement to assess improvement when interventions are used. 
The goal of treatment is usually to reduce pain and improve function. However, sometimes only 
one of these measures may result in improvement. Finally, it is important to remember that often, 
chronic pain is managed not cured (NIH, 2011).  
Clinically Meaningful Improvement with Opioid Use   
     Clinically meaningful improvement with opioids is defined as an improvement in pain and 
function of at least 30% as compared to the start of treatment or in response to a dose change 
(Agency Medical Directors Group, 2015). The pain score improvement or decline was obtained 
for this study. Busse (2018) did a systematic review of RCT’s (random control trials) (26,169 
participants) of opioids for noncancerous chronic pain and found a 0.69 point improvement for 
pain levels when compared with a placebo.  
Age   
     Generally, the literature reveals the presence of a higher prevalence of chronic pain associated 
with advancing age (NIH Medline Plus, 2011).                                                      
                                                  Theoretical Framework 
     Auguste Comte in the 19th century revealed that his theoretical framework of Positivism 
Theory assumes that it is possible to observe social life, and establish reliable, valid knowledge 
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about how it works (Crossman, 2018). Two main principles of Positivism theory are 1) the logic 
of inquiry is identical across all branches of science, and 2) the goal of inquiry is to explain, 
predict, and discover.  Researchers put pain under a microscope when assessing analgesia and its 
effects on pain patients (Alderson, 1998). The use of Positivism Theory (Alderson, 1998) for 
social medicine takes analgesia and its effects on pain into account, as well as context of people 
lives, such as how chronic pain may differ from gender or socioeconomic vantage points. These 
concepts drove the development of this study as it aimed to discover in a logical framework the 
effects of analgesia on chronic pain patient’s numeric pain levels, and urine toxicology results.  
     Positivism theory in health is concerned with the events of cause and effect. If a patient has a 
certain amount of medication there is a certain degree of relief or not that could be measured. 
“The numeric pain rating scale has shown high correlations with other pain-assessment tools in 
several studies” (Haefeli & Elfering, p. S19, 2006). Urine toxicology results will validate that 
medications are in the patients system. Positivist Theory suggests that clinical norms (such as 
CDC’s opioid dosing guidelines) could influence a patient’s chronic pain management outcomes 
(Alderson, 1998). Positivism theory for social medicine means to use objective data as grounds 
for research and treatment (Haefeli & Elfering, 2006) for analgesia.  
                                           Identifying and Defining Variables 
     The variables that are described in this study include the independent clinical variable of the 
daily milligram dosing level of opioids described in daily Morphine Equalization Dosing (MED).      
One dependent variable looks at the patient’s average numeric pain rating score while on 
opioids. Another dependent variable measured a patient’s initial average numeric pain score with 
their pain score during opioid treatment at the clinic was measured. Another dependent variable 
measured the urine toxicology report which compares the urine results from patients in the two 
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different daily dosing groups. The demographic variables include, age, gender, chronic pain 
diagnosis, and type of insurance the patient was currently used.  These variables are illustrated in 
a variable map in figure one (Figure 1) and the variable table (Table 1).  
    To operationalize the variables surrounding the daily dosing groups of opioids a brief 
overview of terminology is necessary. The terminology of the independent dosing variable in this 
study is daily dosing using two different amounts.  When a provider sees the specific measures 
noted such as; daily dosing of 90 mg daily morphine equalization dosing (MED), this means that 
a patient may be on any number of different opioid medications other than morphine or may be 
on morphine. MED is relevant to understand as all narcotics are equalized to the molecule 
morphine. For example, 10 mg daily of Hydrocodone equals the strength of 10 mg daily of 
morphine, this is called the Morphine Equalization Dose (MED).  However, 10 mg of oxycodone 
equals 15 mg of morphine. All opioids are equalized by conversion factors to equal morphine 
abilities. It is used as a standard of measure. Therefore, all opioids carry a morphine equalization 
dosing. When a provider observes 90mg daily MED this means a person’s daily dosing of opioid 
medications equals this strength in dosing to morphine.    
                                                                     Methods 
Design 
     This retrospective chart review study used a descriptive comparative design to compare 
independent variables of patient low dosing of opioids (<90mg daily MED) versus high dosing 
of opioid (≥90 mg daily MED) to various dependent variables. With this design, the researcher 
could answer the proposed research questions and aims. This design compared and assessed 
patients’ level of opioid dosing by, chronic pain numeric average pain scores at initial visit and at 
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return visit after being on opioids for at least a year. The design further compared urine 
toxicology screenings, and other demographic variables such as gender, age, chronic pain 
diagnoses, and insurance type. The design was good for analyzing multiple outcomes. The 
descriptive comparative design was realistic and feasible.  
Sample  
     The target sample was adult chronic pain patients, male and female, living in a rural area in 
N.Y. The pain management clinic functions to provide chronic pain management services to a 
rural small population for any chronic pain condition. The largest proportion of our pain clinic 
population suffer from chronic degenerative disc disease of any area of the spine, spinal stenosis 
of any area of the spine, arthritis in multiple areas, and spinal facet arthropathy. The top five 
treatments for chronic pain at the PM clinic are 1) physical therapy 2) steroid injections 3) 
transcutaneous electrical nerve stimulation (TENS) 4) opioid medications 5) anti-inflammatories, 
muscle relaxers, neuropathy medications and anti-depressants. The outpatient pain management 
clinic sees an average of 100 patients a week, adults of all ethnic origins.  
     This retrospective chart review study involved inclusion and exclusion criteria. Patients were  
included in the study if they had any chronic pain condition within the top four diagnoses; 
degenerative disc disease of any area of the spine, spinal stenosis of any area of the spine, 
arthritis in multiple areas, and spinal facet arthropathy. Patients were seen at the clinic during 
May 1, 2016 thru April 30, 2018 and were on prescribed opioids within the two dosing groups 
for at least a year. The criteria included; <90mg daily MED and ≥90 mg daily MED, age greater 
than 18, and an opioid urine toxicology screening at the clinic.  Patients were excluded from the 
study if they were: 1) being treated for cancer, 2) in palliative or hospice care 3) on the opioids 
Butrans, Belbuca, Tramadol or Nucynta (which is less than 10 percent of this clinic’s 
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population). (The reasoning behind point three is that there is scientific debate about how to 
convert these drugs to the MED).  
Sample Size 
     The target population consisted of 134 patients. After inclusion/exclusion criteria, a total of 
134 adult (>18 years old) patients charts were included. The study compared two groups of 
patients; using the charts of 67 patients from the daily <90mg MED and 67 patients from the 
daily ≥ 90mg MED group.  
     A simple random sampling of 134 health records were conducted for the dates May 1, 2017 
thru April 30, 2018 for this study. Both paper charts and electronic paper charts were used from 
this time frame. A systematic sampling method of every other paper chart within the 
alphabetized charts took place. If the needed data was not found from the paper chart, the data 
was collected on this patient from the eClinical works electronic data system. Collection data 
occurred from patient visits from May 1, 2017- April 30, 2018 but the researcher needed to go 
back occasionally into patients charts until a urine toxicology screen could be found but no 
further back than May 1, 2016. Patients were included only once in the study. Information was 
recorded without identifiers, other than medical record number (1-134) initially for organization.  
Setting 
     Data was collected from the PM clinic that serves a chronic pain population in rural New 
York State. The clinic is partnered with a local hospital. The clinic staff consists of three 
providers, which include one doctor of anesthesiology specializing in pain management, one 
doctor specializing in pain medicine, and a nurse practitioner specializing in pain medicine, two 
nurses, four medical assistants, and two receptionists. The clinic serves approximately 400 
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patients a month.  Patients are usually seen every three months if they are on any opioid 
medication but may come in more due to a pain exacerbation. The clinic has a clientele of 
approximately 1000 patients, all of whom are adults, with a third or more on daily opioids. 
Patients are usually seen 3-4 times a year when stable but more often if pain is exacerbating. The 
receptionist handed the patient the numeric pain rating scale and opioid urine toxicology 
screening cup when they enter for their appointment. The receptionist was responsible for 
scanning data from the numeric pain rating scale for average pain since last visit and placing the 
results of the urine toxicology screenings into the patients’ medical record. These reports are 
then reviewed by the provider with the patient.                    
Measurements 
     Descriptive analysis analyzed the frequency and percentages of the following; age, opioid 
daily dosing of ≥90mg MED versus opioid daily dosing of <90 mg MED, initial pain scores and 
pain scores after a year on opioids, urine toxicology screenings, insurance type and chronic pain 
diagnosis (Table H).  The study used a two-tailed independent t-test, with an effect size (Cohen’s 
d) of 0.5, a statistical power level of 0.8% and an error probability level of 0.05 for the analysis.                 
                                                           Instruments  
     The variables that were measured in this retrospective descriptive comparative design study 
included the following demographics; gender, insurance status, age, and primary diagnosis at the 
first visit. The independent variable measured was the opioid dosing level group of high versus 
low groups. Dependent variables include the difference between the initial visit average numeric 
pain score and the numeric pain score from a visit after the patient was on opioids for a year. 
These results were compared with the patients’ urine toxicology reports while they were on 
opioids.  
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     The PM clinic has paper charts on each patient with their recorded pain scores and the results 
of their urine toxicology screenings until May 2017, then the charts became electronic. The 
numeric pain scale average since last visit was recorded after a patient fills it in at each visit, and 
an opioid urine toxicology is done at least yearly by a medical assistant, or receptionist, and sent 
to the urine toxicology laboratory. 
     When the opioid urine toxicology screening was performed the patient was handed a urine 
cup with lid and asked to use the patient restroom, which was within sight of the 
reception/medical assistant area. The patient then used the bathroom alone. Then the urine was 
returned to receptionist or medical assistant. All opioid drugs were then listed on the 
Ameritox/Dominion urine form by the medical assistant or receptionist that the patient stated 
they were taking. The patient signed that this was their urine and that they agree with the 
medications listed to be tested, then the bag was sealed with the patient watching. The bag with 
the cup of urine was mailed to the urine toxicology company by United Postal Service (UPS). 
Opioid urine toxicology screenings at the pain management clinic are sent to Ameritox or 
Dominion Laboratories (2018) for testing and results (Appendix C). The results include: 1) 
medications patient states they are taking- are they in the urine or not 2) medications in urine not 
stated by patient 3) illegal medications found in urine. The patients whose office visits are paid 
for by Workers Compensation are sent to Dominion and all others to Ameritox. Dominion has an 
agreement of business association with Workers Compensation in N.Y. Both laboratories return 
the urine results with the same data analysis and methods of screening.  Both laboratories use gas 
chromatography-mass spectrometry and liquid chromatography- tandem mass spectrometry. 
These methods are considered medical standard of care and the gold standard for urine 
toxicology screenings (American Medical Association, 2016).   
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     The laboratory returns the results (usually within a week) with positive (pass) or negative 
(fail) for each medication that was listed on the original intake that the patient verified. The lab 
sends results for drugs not listed by the patient, such as illicit; heroin, cocaine, 
methamphetamine, and benzodiazepines or other drugs in the muscle relaxant class. False-
positives by the labs are not taken into consideration at this office. If a patient disagrees with the 
urine results and feels they are a false negative, they will need to find another provider at a 
different clinic or continue with the recommended prescribing changes or other treatment plan 
made by the provider.  
Urine Toxicology Screening 
     The scoring for this study from the urine toxicology screenings was positive for a pass and 
negative for a fail. A positive (pass) means that what the patient states they have been taking 
their opioid medications are 1) prescribed 2) and were documented in the urine toxicology 
screening. A negative (fail) may mean that 1) the patient is not taking their opioid medications as 
prescribed  2) no logical reason for missing dosing (such as hospital stay) as determined by 
provider. (Appendix C) 
Numeric Average Pain Score   
     The numeric pain rating scale average (Figure 2) since last visit are asked as each visit by the 
receptionist or medical assistant. Also, on the initial visit for pain management, the average 
numeric pain score was taken. The patient was given this form to fill out and circles a number 
between 0-10 that best describes their pain average. Zero represented no pain at all, the mid-
range numbers are moderate pain, and the upper numbers represented the worst possible pain.  
Dosing Group   
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     The CDC’s Opioid Dosing Guidelines form a general framework for dosing groups for this 
study (Appendix D). These guidelines were disseminated in 2016. 
                                                 Data Collection Procedure  
    IRB approval was obtained and the data extraction for this descriptive-comparative study 
design was collected from patient’s paper and electronic chart data with dates ranging from May 
1, 2016 through April 30, 2018. The eligible patients were determined by randomly selecting 
every other paper chart, noting the dosing of opioids the patient is on, then placing the data in the 
high or low dose group into the code sheet. If a patient was not on opioids, that chart was 
skipped. The results of the urine toxicology screen, the initial visit average numeric pain score, 
the visit average numeric score after a year on opioids and the demographic data, such as age, 
gender, insurance type, and diagnosis were entered into the code sheet ( Appendix A & B). 
     I was the student investigator and collected and entered the data into the code sheet. I have 
been trained in proper collection and analysis procedures. No additional data collectors were 
used. Data accuracy check was conducted for 10% of the data, for which I utilized an expert Dr. 
Juan Diego Harris (pain management doctor at pain management setting) who is familiar with 
the pain management clinic’s opioid urine toxicology screening and numeric pain rating scale 
assessment. He did not look at the patient collection of records I used but verified the process of 
collection. Data collection occurred at the pain management clinic.                                                           
                                                        Data Analysis Plan 
            Data was imported to IBM SPSS (version 24), which is a statistical software that assists 
in data mining and analytics. Descriptive analysis looked at the frequency and percentages of the 
following; age, opioid daily dosing of ≥90mg MED versus opioid daily dosing of <90 mg MED, 
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urine toxicology screenings, gender, insurance type, and chronic pain diagnosis (Table H).  The 
study used a two-tailed independent t-test, with an effect size (Cohen’s d) of 0.5, a statistical 
power level of 0.8% and an error probability level of 0.05 for the analysis.  
                                                        Ethical Considerations 
     My retrospective study was submitted to the IRB at The George Washington University 
(GWU) for consideration and was approved as an Exempt Study. A letter of approval from the 
Pain Management Clinic office authority with their permission was obtained for conducting the 
study during the specified dates and was submitted to the IRB at GWU. In order to maintain the 
privacy of each subject, all patient data was placed into the coding sheet data and were de-
identified other than a made-up numeric patient identifier (1-134).  In order to maintain the 
confidentiality of the code sheet, and SPSS data, the information was stored by the primary 
contact (student researcher) on a secure hard drive with antivirus protection on a laptop 
computer. The laptop computer was stored behind a locked door for which the student researcher 
had the key. The student researcher had the only password to the computer which was protected 
by a firewall. The student researcher had the only password to the code sheet, SPSS, and the only 
password to the computer used. The data was backed up on a thumb drive, with password 
protection, accessible only to the student researcher. 
  Data Timeline   
     Data collection began September 2018 and continued until November 2018. The study was 
launched and complete data collection and data entry on the appropriate code sheet was 
completed. The student researcher reported monthly to the primary advisor with issues and the 
progress of the DNP project. The study abstract and research poster was developed during 
September-December 2018. In December-January 18-2019 the data entry, data cleaning, and 
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data analysis was completed and findings written into the final draft. The final draft was 
submitted in February, 2019. In March 2019, the final paper was due. In April, 2019 the final 
electronic poster will be submitted along with the DNP project to the Himmelfarb Library. In 
May, 2019 the project is due to The George Washington University DNP Repository.         
                                                                       Results                                                                                                               
Demographics and Clinical Characteristics  
Urine Toxicology Results   
      Data analyses were done using descriptive analytics and the independent t test.  Of the 134 
patients, 9 (6.7%) failed urine toxicology screenings, 6 from the (<90mg MED low dose group) 
and 3 (≥90mg MED high dose group) (Table 3). Of those with passed urine toxicology’s (n=125, 
93.3%). Of those with passed urine toxicology’s (n=61, 48.8%) were in the low dosing group 
and (n= 64, 51.2%) were in the high dosing group. There was not a statistically significant 
difference between the opioid dosing level group and failed urine toxicology (p=0.300) (Table 
3). Of interest no statistically significant difference was found between age groups and patients 
with negative urine (p=0.315).      
Pain Scores Results  
     Data analyses were done with descriptive analytics and the independent t test. Overall, pain 
scores from the first visit at the pain management clinic to a visit after a year on opioids in all 
134 patients went from a 7.31/10 to 6.43/10 (change of -0.88). Of those in the low dose group 
(<90mg MED) changed from 7.24/10 to 6.21/10 (change of -1.03). Of those in the high dose 
group (≥90mg MED) changed from 7.39/10 to a 6.64/10 (change of -0.75) (p=0.953) (Table 3). 
OPIOID DAILY DOSING  23 
The difference in pain scores between the two dosing levels groups was small and not 
statistically significant. All results under pain scores were not found to be statistically significant. 
Insurance Type Results 
     Data analyses were done with descriptive analytics and the independent t test on insurance 
variables. Participants with Medicaid had the highest number of people in this study under 
insurance types with 32% (n= 43).  Medicare was second with 29.7% (n=39). Workers 
Compensation was 19.4% (n= 26), and private insurance were equal 19.4% (n=26).  By dosing 
level group, Medicaid had the most people in the low opioid dosing level group and Medicare 
the most people in the high opioid dosing level group (Table 3). Overall, Medicaid’s low dosing 
group was (n=19, 28.4) and high dosing group (n=24, 35.8%). Medicare’s low dosing group was 
(n=14, 20.9%), and high dosing group (n=25, 37.3%). Workers Compensation in the low dosing 
group was (n=18, 6.9%), and high dosing group (n=8, 11.9%). Private insurance for the low 
dosing group was (n= 16, 23.9%) and the high group (n=10, 14.9%).  A statistically significant 
difference was found in insurance types with the different dosing groups (p=0.030) (See Table 
3).  
Age Results   
     Data analyses were done with descriptive analytics and the independent t test.  The 18-40 age 
group had the lowest number of people 9.0% (n=12).  Of this age group there were (n= 5, 7.5%) 
in the low dosing group (<90mg MED) and (n=7, 10.4%) in the high dosing group (≥90mg 
MED). Most people in this study were from the 41-65 age group 70.9% (n=95).  Of this group 
there were (n= 49, 73.1%) from the low dosing group and (n=46, 68.7%) from the high dosing 
group.  In the 66-81 age group there were 20.1% (n=27). There were (n=13, 19.4%) from the low 
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dosing group and (n=4, 20.9%) from the high dosing group.  A significant statistical relationship 
was not found between age and opioid dosing level group (p=0.793) (Table 2).  
Gender Results 
     Of the 134 patients, 53% (n=71) were male and 47% (n= 63) were female.  In the low dosing 
(<90mg MED) daily opioid group, there were (n=33, 49.3%) males and (n=34, 50.7%) females. 
In the high dosing daily opioid group (≥90mg MED) there were (n=38, 56.7%) male and (n=29, 
43.3%) female. There was not a significant statistical relationship between opioid daily dosing 
level group and gender (p=0.387) (Table 3).   
Chronic Pain Diagnosis Results   
     Data analyses were done with descriptive analytics. Participant who had degenerative disc 
disease at any level of the spine had the largest chronic pain diagnosis at 45.5% (n= 61). The 
second largest diagnosis was facet arthropathy of any level of the spine 29.1% (n=39). Multiple 
areas of arthritis were third at 17.2% (n=23). Lastly, stenosis at any area of the spine was 8.2% 
(n=11). In the categories of low and high opioid dosing groupings, degenerative disc disease was 
almost equal in numbers for high and low dosing groups. The low dosing group included 30 
patients (44.8%) with degenerative disc disease and included 31 patients (46.3%) from the high 
dosing group. The low dosing group for facet arthropathy of the spine included 3 patients 
(34.3%), and included 16 patients (23.9%) from the high dosing group. The low dosing group for 
multiple areas of arthritis included 12 patients (17.9%) and included 11 patients (16.4%) from 
the high dosing group. The low dosing group for spinal stenosis included 2 patients (3.0%) and 
included 9 patients (13.4%) from the high dosing group. 
Improvement/Decline with Opioids Results 
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      Data analyses were done with descriptive analytics and the independent t test. 32 patients 
(23.9%) received 30% or greater in reduction of their chronic pain within either opioid dosing 
group. Of these 32 patients 17 were from the (<90mg MED-low) and 15 (≥90 mg MED-high) 
(Table 3). Final pain scores with opioids were 6.21/10 in the low dose group and 6.64/10 in the 
high dose group (p=0.178) (Table 3). 42% (n=57) of patients experienced 0-30% worsening of 
their pain level while on opioids for chronic pain. Patients with any level of improvement in their 
pain level included 77 patients (57.5%) while on opioids ranging from 10 percent to 30 percent 
improvement or in some cases higher (Table 3). The improvement or decline were not shown to 
have a statistically significant relationship with the opioid dosing groups.                                             
                                                              Discussion     
     The chronic pain management clinic in this study is like many others across the U.S, who are 
trying to find the balance of managing opioid misuse and helping people manage their daily 
chronic pain. 
Urine Toxicology’s   
     9 out of 134 (6.7%) people received urine toxicology failures in this study, which indicates 
misuse of medication, however, this was slightly lower than the studies cited in the paper’s 
literature review. Morasco (2017) places the national average of opioid misuse at 7.6%-8.2%. 
Whereas, Chou (2015) estimates the opioid misuse rate at 8-16%. Yet, the information about the 
rate of misuse in my study will be helpful to alert providers and patients at clinics to the 
continual real risk of opioid misuse, whether at a low or high opioid dosing level.  
Pain Levels   
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     Overall, changes in pain scores from the first visit at pain management to a visit with a year 
on opioids in all 134 patients went from a 7.31/10 to a 6.43/10 (change of -0.88). Low dose 
group (<90mg MED) changed from 7.24/10 to 6.21/10 (change of -1.03). High dose group 
(≥90mg MED) changed from 7.39/10 to a 6.64/10 (change of -0.75) (p=0.953) (Table 3). While a 
statistical relationship was not found, it is interesting on an individual level that 23.9% (n=32) 
were found to have a 30% or greater improvement of their pain level irregardless of dosing. The 
findings of pain level improvement or lack thereof in this study agreed basically with both 
studies (Henry, Wisley, Melnikow & Losif, 2015) and (Von Korff et al., 2011), who found that 
there was less than one point level improvement with the use of opioids at any dosing group in 
their studies. This information is helpful in that the results point to the importance of managing 
patients’ daily pain improvement expectations while on opioids carefully, as the improvement 
may be small. This informs providers and patients to look at multiple other ways to manage 
chronic pain for the long term rather than just with opioids.  
Gender   
     Han et al., (2015) and Boscarino et al., (2016) found larger differences in opioid misuse 
between the genders; Han et al., (2015) place males with a higher rate whereas Boscarino et al., 
(2016) place females higher. Darnell, Stacey & Chou (2012) also suggest that women have more 
chronic pain than men and therefore use higher dosages. The results from this current study 
disagree with their findings; the current study found that males and females presented almost 
equal in urine toxicology failure rates (M=5, 55.6% & F=4, 44.4%). The current study found that 
men sought chronic pain management more than females, though not significantly (M=71 (53%) 
& F=63 (47%). Further, the current study revealed that males and females were equal in the low 
dosing opioid category, but for the high dosing group men were more likely to use high daily 
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opioid doses than females (M=38 (56.7%) & F=29 (43.3%). This is important as it reveals there 
may be higher daily opioid dosage usage with males, which may influence programs in our area 
that study male opioid misuse. Further research should look at occupations in the target region of 
study or other possible variables (e.g. socioeconomic status) that could account for the 
differences in the current study. One theory for this finding may be that men in our region are in 
high impact jobs, such as farming, construction, scrap metal work, and may need higher dosing 
of medications in order to keep working.  
Insurance Type   
     The insurance types at the pain clinic showed a statistically significant relationship to the low 
daily opioid dosing versus high daily opioid dosing groups. Medicaid was the highest used 
insurance in the current study (32.1%) compared to Medicare (29.1%), Workers Compensation 
(WC) (19.4%), and private insurance (19.4%).  The insurance type in the current study suggests 
and agrees with Jeffery et al., (2018) that workers who have private insurance and workers 
compensation do not present in high numbers at the pain management clinics. Second, Jeffrey et 
al., (2018) reveals that Medicare patients were daily dosed at around the 56 mg MED in his 
study, whereas, the current study considered high dosage to be ≥ 90mg MED. 37.3% of the 
patients were on Medicare in the current study. My findings revealed private insurance and WC 
only had 26% of the patients in the high dose group while Medicare and Medicaid together had 
74% in the high dosing group. Chronic pain patients who presented at the pain clinic used 
insurances other than private or WC 78% of the time.  This information is important as it reveals 
possible financial struggles people with chronic pain face. With private insurance and WC there 
was a 22.2% urine toxicology failure and Medicare and Medicaid a 77.6% urine toxicology 
failure. One possible explanation for the relationship found is that the Workers Compensation 
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(WC) board does not allow or approve many people to use high dose opioids (>90mg MED) 
while on WC.                                                        
                                                             Limitations 
     One limitation of the study was the limited data variables researched in the study. The study 
provides good baseline data that could give providers and patients a starting point to discuss 
goals and values with opioid use. However, assessing patients functioning while on opioids 
could give further insight for both provider and patient. Another limitation of the study was that 
the sample population was obtained from one specialty clinic in a small (less than 10,000 in 
population) rural pain management clinic. A larger population in a more diverse setting would 
have significantly increased the generalizability of the results. 
                                              Implications/Recommendations   
     The study’s findings could be useful to improve opioid prescribing by providers and patients. 
Patients and providers can judge over time using the pain scale, how opioids have been helpful 
or not, even if there is opioid misuse or not. For example, instead of following last month’s 
prescription rate, prescribers could follow the actual pain score a patients reports along with their 
urine toxicology results. Prescribers need to help patients understand the pain scales value for 
their future of planning of their opioid pain management strategy.  Providers can benefit from 
learning about patients at their individual practice in order to discuss and form new insights for 
their prescribing practices of opioids. Patients can benefit from this information about their own 
pain scores improvement or not with opioids, which could influence their further decisions about 
use. Further, the study supports the idea of finding other ways to support and treat chronic pain 
patient’s pain levels as opioids according to this study only improved around half of its patient’s 
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average daily chronic pain and improvement overall was small. Providers need to help patients 
manage their expectations of what opioids can do, along with their risks. Moreover, providers 
need to reconsider providing opioids to those patients where no benefit is occurring and seek 
new ways of managing of their patient’s pain levels. Workers Compensation has the lowest 
number of high dosage (≥90 MED) patients in my study. Further, Workers Compensation is the 
least likely to pay for high (≥90 MED) of daily opioids.                                                         
                                                            Sustainability 
     The method of integrating and the gathering of this type of data for the future from a pain 
management practice that prescribes opioids for chronic pain patients should be done within the 
IT department or implemented into any IT program. Data such as documented improvement in 
pain levels, functioning over time with opioids, and urine toxicology results should be assessed 
by the provider and the patient at each visit. 
                                                           Conclusions   
     Concerns within healthcare about opioid prescribing are increasing for patients, prescribers 
and communities. The CDC (2016) has issued recommended daily dosing levels of opioids for 
chronic pain management. Higher rates of failed (negative) urine toxicology, which indicates 
misuse, were not found in the higher dosing group in this study. However, the higher rates of 
misuse were found in the patients in the low dosing group. This could be possibly explained in 
that the misuse was caught early in the course of the problem. Possibly, due to frequent enough 
urine toxicology screenings. Chronic pain patients and providers have concerns about improving 
pain levels and decreasing risks of opioids. Of 134 patients on opioids for over a year, only 
57.5% showed improvement in their pain levels with opioids, though improvements were small. 
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Many (46.5%) showed no improvement or worsening of their pain levels on opioids. Opioids 
urine toxicology failure rate was 6.7%. Assessing pain levels and urine toxicology over time, at 
each visit, by patient and provider while using prescribed opioids is a useful practice. Further 
research for alternative methods of chronic pain reduction are needed.   
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                                                                   Figure 1 
                                                        Concept Map for Variables 
 
                                                             
                                                          
 
                                                                                                   
 
Chronic pain disorder 
needing opioid treatment
Numeric pain rating average 
with treatment ≥90 mg 
daily MED opioids vs  ≥ 90 
mg daily MED
Urine toxicology screening 
with treatment <90mg daily 
MED vs ≥90 mg daily MED
Gender, insurance and 
demographic varaibles
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                                                               Figure 2 
                                       Example of Numeric Pain Rating Scale 
                     
                          Initial Visit- What is your average pain level in the last week? 
                      Follow up visit-What is your average pain level since your last visit? 
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                                                            Variables 
                                                               Table 1 
        Variable Type of Variable        Theoretical              





Independent Morphine Equalization 
Dosing (MED) is a 
standard conversion of 
all opioids to strength 
of Morphine.  
1= < 90mg MED 
 
2= ≥ 90mg MED 
 
For one year or 
more 




Dependent -nominal Ameritox or Dominion 
Lab urine toxicology 
screening done yearly, 
pass means opioid 
prescribed medications 
are in the urine and 
fail means that opioids 
prescribed are not in 
urine or illicit or non-
prescribed drugs are 
found in urine testing.  
1= Positive (pass) 
 






Dependent- interval Numeric Pain rating 
scale 0-10 with 0 
being no pain and 10 
being worst pain ever.  
 
0-10 scale = actual 
score 





Dependent-Interval Numeric Pain rating 
scale 0-10 with 0 
being no pain and 10 
being worst pain ever. 
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• Actual Age Demographic Chronological age in 
years 
Actual Age 
• Chronic Pain 
Diagnosis at 
Visit  
Demographic Top Disorders seen at 
Pain Management 
Clinic 
1= Spinal Stenosis- 
Lumbar, Thoracic, 
Cervical, 2= 
Multiple Areas of 
Arthritis, , 3= 
Degenerative Disc 






• Gender Demographic Patients biological sex 1=Male 
 
2= Female 
• Ethnicity in 
Pain Clinic 
Setting 
Demographic A person’s genetic or 
biological 
characteristics. 
As recorded by 
admitting provider 
1= Caucasian 
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                                                                  Table 2 
 






Low Opioid Dose  
(n=67) 
Freq (%) 




     
Age     x2 =0.465, p=0.793 
18-40 12 (9.0%)     5   (7.5%)      7   (10.4%)  
41-65 95 (70.9%)     49 (73.1%)      46 (68.7%)  
66-81 27 (20.1%)     13 (19.4%)      14 (20.9%)  
     
Chronic Pain 
Diagnosis 







                                   
     2   (3.0%) 
 
    9   (13.4%) 
 
Multiple Areas of 
Arthritis 
23 (17.2)      12 (17.9%)     11 (16.4%)  
Degenerative Disc 
Disease of Spine 
61 (45.5%)      30 (44.8%)     31 (46.3%)  
Facet Arthropathy of 
Spine 
39 (29.1)      23 (34.3%)      16 (23.9%)  
     
Ethnicity     *NA 
Caucasian 133 (99.3%)       66 (98.5%)         67 (100%)  
Non-white American 1    (0.7%)        1   (1.5%)          0   (0%)  
     
*Statistical test not performed due to small number of cases in subcategories. 
                                     
 
 
                                                                    Table 3 
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                               Opioid Dosing and Related Variables Hypothesis Testing 
 
   Sample  Low Opioid 
Dosing 
 High Opioid 
Dosing 
Statistics 
     
Variables Total Sample ≤ 90mg MED ≥90mg MED   
        134          67           67  
     
Urine 
toxicology  
      χ2=1.072, p=0.300 
Positive 125 (93.3%) 61 (91.0%) 6 (95.5%)   
Negative 9     (6.7%) 6   (9.0 %) 3 (4.5%)   
     
Pain score 
First Visit 
7.31 (1.758) 7.24 (1.759) 7.39 (1.766) t= -0.490 p=0.625 
     
Pain Score 
Recent Visit 
6.43 (1.857) 6.21 (1.887) 6.64 (1.815) t= -1.353 p=0.178 
     
Insurance       χ2=8.915, p=0.030 
Medicaid 43 (32.1%) 19 (28.4%) 24 (35.8%)   
Private 25 (18.7%) 15 (23.9%) 10 (14.9%)   
Medicare 39 (29.1%) 14 (20.9%) 25 (37.3%)  
Workers Comp. 26 (19.4%) 18 (26.9%) 8   (11.9%)  
     
Gender       χ2=0.749 p=0.387 
Male 71 (53%) 33 (49.3%) 38 (56.7%)   











    χ2=1.596, p=0.953 
≥30% Improvement 32 (23.9%) 17 (25.4%) 15 (22.4%)  
≥20% Improvement 22 (16.4%) 12 (17.9%) 10 (14.9%)  
≥10% Improvement 23 (17.2%) 10 (14.9%) 13 (19.4%)  
  0% Improvement 26 (19.4%) 14 (20.9%) 12 (17.9%)  
≤10% Decline 13 (9.7%) 6   (9.0%) 7   (10.4%)  
≤20% Decline 12 (9.0%) 6   (9.0%) 6   (9.0%)  
≤30% Decline 6   (4.5%) 2   (3.0%) 4   (4.5%)  
Significant result is bolded 
                                                                 Appendix A                                            
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                                                         Data Collection Form 
Patient 
#ID 
    
 
    
1          
2          
3          
4          
5          
6          
7          
8          
9          
10          
11          
12          
13          
14          
15          
16          
17          
18          
19          
...          
 
*1= Spinal Stenosis- Lumbar, Thoracic, Cervical, 2= Multiple Areas of Arthritis, 3= 
Degenerative Disc Disease of Spine, 4=Facet Arthropahy of Spine 
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                                                          DATA CODEBOOK 
Patient ID Code  1-134 
 
Opioid Dosing Level 1= <90mg daily MED 
 
2= ≥90 mg daily MED 
 
Opioid Urine Toxicology Results 1= Positive (pass) 
 
2= Negative (fail) 
 
Numeric Pain Rating Scale Average Since 
Last Visit 
0-10 scale= actual score 
 
 









Primary Diagnosis at Visit 1= Spinal Stenosis- Lumbar, Thoracic, 
Cervical  
2= Multiple Areas of Arthritis 
3= Degenerative Disc Disease of Spine, 
4=Facet Arthropathy of Spine 
 
Initial Visit Numeric Average Pain Score 0-10 scale= actual score 
 
Actual Age in Years Actual Age 
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                             Abbreviated CDC Opioid Dosing Guidelines for Chronic Pain 
 
 
 
  
 
